Galera Therapeutics, Inc.

GRTX

Galera Therapeutics, Inc.

GRTX

Insider Sentiment (TTM):

Last Purchase:2024-12-30Last Sale:2025-11-20Shares Purchased (TTM):0Shares Sold (TTM):70,000

Institutional Sentiment:

As of:2024-06-30Institutional Shares Owned:4,414Shares Outstanding:54,392,170Institutional Ownership Pct.:0.01%

Earnings Market Reaction:

Filing Date:2026-05-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Cash And Cash Equivalents At Carrying Value	6	6	4	5	7	8	8	11	13	18	24	24
Short Term Investments	-	-	-	-	-	-	-	-	-	0	4	14
Assets Current
Assets Current	6	7	5	6	8	10	9	12	15	22	31	42
Restricted Cash	-	-	-	-	-	-	-	-	-	-	0	0
Prepaid Expense And Other Assets Current	1	1	0	1	1	1	0	1	2	3	3	3
Restricted Cash Current	-	-	-	-	-	-	-	-	-	0	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	2	2
Property Plant And Equipment Net	-	-	-	-	-	0	0	0	0	0	0	0
Indefinite Lived Intangible Assets Excluding Goodw…	-	-	-	-	-	0	0	2	2	2	2	2
Assets	6	7	5	6	8	10	9	16	20	26	38	48
Goodwill	-	-	-	-	-	0	0	1	1	1	1	1
Liabilities And Stockhold…
Operating Lease Right Of Use Asset	-	-	-	-	-	0	0	1	1	1	1	1
Liabilities
Liabilities	1	1	152	151	152	154	152	154	154	157	164	163
Preferred Stock Value	-	-	-	-	-	-	0	0	0	0	0	0
Long Term Debt And Capital Lease Obligations Curre…	-	-	-	-	-	0	0	0	0	0	0	0
Accounts Payable Current	1	0	0	0	1	1	0	1	1	1	4	6
Liabilities Current
Accrued Liabilities Current	0	0	0	0	0	0	1	1	1	3	9	8
Liabilities Current	-	1	1	0	1	2	1	2	2	5	13	14
Royalty Guarantees Commitments Amount	-	0	151	151	151	151	151	151	151	151	150	148
Warrants And Rights Outstanding	-	0	0	0	0	1	-	-	-	0	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	-	-	-	-	-	0	0	1	1	1	1	1
Stockholders Equity
Stockholders Equity	1	4	-149	-148	-147	-148	-143	-138	-135	-131	-127	-115
Additional Paid In Capital Common Stock	310	311	311	311	311	308	308	308	307	306	305	302
Deferred Tax Liabilities Derivatives	-	-	-	-	-	0	0	0	0	0	0	0
Retained Earnings Accumulated Deficit	-309	-307	-460	-459	-458	-456	-451	-446	-442	-437	-432	-417
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities And Stockholders Equity	6	7	5	6	8	10	9	16	20	26	38	48
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	75	75	75	75	75	75	54	54	54	54	54	44
Shares Outstanding	75	75	75	75	75	75	54	54	54	54	54	44

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.00%	-8.50%	-	-	-	-	-	-	-	-	-	-
2025	-1.25%	22.50%	-4.17%	-24.78%	-15.71%	19.47%	1.27%	-3.16%	-10.55%	-16.16%	102.02%	91.92%
2024	-38.07%	-24.49%	-34.55%	5.49%	6.34%	-29.58%	68.33%	46.67%	27.67%	-17.80%	-19.17%	-6.67%
2023	-	-	-	-34.00%	-43.33%	-61.53%	-7.79%	7.15%	24.95%	31.43%	40.00%	-32.86%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	-	11.00	8.20	17.14	7.75	6.00	9.74	5.63	7.54	4.36	2.47	3.08
Quick Ratio	-	9.88	7.48	15.07	6.86	5.36	9.25	5.06	6.69	3.68	2.25	2.85
Working Capital	-	6.45M	4.30M	5.60M	6.59M	8.34M	7.99M	9.84M	13.17M	16.67M	18.62M	28.38M
Leverage & Debt
Debt to Equity	-	0.16	-1.02	-1.02	-1.03	-1.04	-1.06	-1.12	-1.15	-1.20	-1.30	-1.42
Interest Coverage TTM	-	-	-	-	-	-	-28.18	-9.80	-5.56	-4.32	-4.08	-3.74
Debt Ratio	-	0.09	30.32	25.03	19.84	15.22	17.07	9.43	7.85	6.02	4.35	3.38
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	1.52	1.51	-0.09	-0.13	-0.16	-0.34	-0.36	-0.54	-0.84	-1.33	-1.53	-1.65
Free Cash Flow Per Share TTM	-0.05	-0.06	-0.07	-0.08	-0.10	-0.22	-0.36	-0.55	-0.70	-1.01	-1.08	-1.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-1,040.26%	-895.65%	-55.33%	-55.49%	-65.15%	-68.29%	-71.85%	-58.80%	-29.05%	-5.05%	10.89%	1.74%
EPS Growth (1Y)	-1,040.26%	-541.29%	-75.33%	-75.42%	-80.76%	-74.15%	-76.47%	-67.49%	-54.09%	-39.23%	-34.60%	-36.42%
Calculated Values
Free Cash Flow TTM	-4.69M	-6.05M	-6.79M	-8.33M	-9.59M	-12.15M	-19.73M	-29.95M	-38.03M	-44.91M	-48.93M	-45.62M
Net Debt	-5.50M	-6.38M	-4.47M	-5.23M	-6.69M	-8.29M	-8.46M	-10.59M	-13.33M	-18.12M	-24.30M	-24.22M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-20Sale

Owner: Sorensen, Mel

Title: President and CEO

Shares: 70,000

Price/Share: $0.02

Value: $1,400.00

Shares Owned: 195,029

Relationship: Director,Officer

Ownership: Direct

2024-12-30Purchase

Owner: Chang, Nancy T

Title: -

Shares: 7,644,932

Price/Share: $0.07

Value: $535,145.24

Shares Owned: 7,644,932

Relationship: Director,TenPercentOwner

Ownership: Direct

2024-08-16Sale

Owner: Sorensen, Mel

Title: President and CEO

Shares: 67,015

Price/Share: $0.07

Value: $4,691.05

Shares Owned: 265,029

Relationship: Director,Officer

Ownership: Direct

2024-04-19Purchase

Owner: Schneid, Yair

Title: -

Shares: 100,000

Price/Share: $0.19

Value: $19,000.00

Shares Owned: 10,823,610

Relationship: TenPercentOwner

Ownership: Direct

2024-03-28Sale

Owner: Altamont, Pharmaceutical …

Title: -

Shares: 693,076

Price/Share: $0.15

Value: $103,961.40

Shares Owned: 1,080,000

Relationship: Other

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-20	Sorensen, Mel	Director,Officer	President and CEO	Direct	Sale	70,000	0.02	$1,400.00	195,029	4
2024-12-30	Chang, Nancy T	Director,TenPercentOwner	-	Direct	Purchase	7,644,932	0.07	$535,145.24	7,644,932	4
2024-08-16	Sorensen, Mel	Director,Officer	President and CEO	Direct	Sale	67,015	0.07	$4,691.05	265,029	4
2024-04-19	Schneid, Yair	TenPercentOwner	-	Direct	Purchase	100,000	0.19	$19,000.00	10,823,610	4/A
2024-03-28	Altamont, Pharmaceutical …	Other	-	Indirect	Sale	693,076	0.15	$103,961.40	1,080,000	5
2024-02-08	Schneid, Yair	TenPercentOwner	-	Direct	Purchase	150,000	0.17	$25,500.00	8,043,203	4
2023-03-16	Bachleda, Mark	Officer	Chief Commercial Officer	Direct	Purchase	11,000	2.25	$24,750.00	11,000	4
2023-03-13	Degnan, Chris	Officer	Chief Financial Officer	Direct	Purchase	10,000	1.96	$19,600.00	10,000	4
2023-03-10	Sorensen, Mel	Director,Officer	President and CEO	Direct	Purchase	100,000	1.68	$168,000.00	332,044	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2024-06-30

0.01%

Inst. Shares: 4,414

Shares Outstanding: 54,392,170

2024-03-31

11.28%

Inst. Shares: 6,136,781

Shares Outstanding: 54,392,170

2023-12-31

19.44%

Inst. Shares: 8,661,592

Shares Outstanding: 44,549,285

2023-09-30

18.71%

Inst. Shares: 8,508,033

Shares Outstanding: 45,477,952

2023-06-30

42.68%

Inst. Shares: 18,317,010

Shares Outstanding: 42,916,962

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2024-06-30	4,414	54,392,170	0.01%
2024-03-31	6,136,781	54,392,170	11.28%
2023-12-31	8,661,592	44,549,285	19.44%
2023-09-30	8,508,033	45,477,952	18.71%
2023-06-30	18,317,010	42,916,962	42.68%
2023-03-31	18,476,009	35,196,134	52.49%
2022-12-31	11,709,867	35,196,134	33.27%
2022-09-30	10,388,041	26,823,546	38.73%
2022-06-30	10,516,489	26,821,303	39.21%
2022-03-31	11,246,268	26,749,379	42.04%
2021-12-31	10,959,541	26,749,379	40.97%
2021-09-30	19,672,554	26,304,920	74.79%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Galera Therapeutics, Inc. (GRTX) — SEC Financial Statements & Analysis

Galera Therapeutics, Inc. (GRTX) is a pharmaceutical preparations company, incorporated in DE. Galera Therapeutics, Inc. trades on OTC as: GRTX. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Galera Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.16x. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.16x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Galera Therapeutics, Inc. in?

Galera Therapeutics, Inc. (GRTX) operates in the Pharmaceutical Preparations industry.

What exchange does GRTX trade on?

Galera Therapeutics, Inc. (GRTX) trades on the OTC.

Where is Galera Therapeutics, Inc. incorporated?

Galera Therapeutics, Inc. is incorporated in DE.